[{"from": "human", "value": "Could you provide a description of this molecule? [C][C@@H1][C@@H1][C@H1][Branch2][Ring2][#Branch1][C][=Branch1][C][=O][N][Ring1][Branch1][C][=Branch2][Ring1][#Branch1][=C][Ring1][Branch2][S][C@H1][C][C@H1][Branch1][Branch1][N][C][Ring1][Branch1][C][=Branch1][C][=O][N][Branch1][C][C][C][C][=Branch1][C][=O][O][C@@H1][Branch1][C][C][O]"}, {"from": "gpt", "value": "The molecule is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.  In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and [DB12107] and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria."}]